<?xml version='1.0' encoding='UTF-8'?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="pmc-domain-id">798</journal-id><journal-id journal-id-type="pmc-domain">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>American Academy of Neurology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5664300</article-id><article-id pub-id-type="pmcid-ver">PMC5664300.1</article-id><article-id pub-id-type="pmcaid">5664300</article-id><article-id pub-id-type="pmcaiid">5664300</article-id><article-id pub-id-type="pmid">28978655</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000004594</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2016772202</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>13</subject><subject>25</subject><subject>38</subject><subject>120</subject><subject>128</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Change in multimodal MRI markers predicts dementia risk in cerebral small vessel disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zeestraten</surname><given-names initials="EA">Eva A.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>(1) Bioclinica, imaging operations associate, 1 year</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>(1) Bioclinica, wages</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lawrence</surname><given-names initials="AJ">Andrew J.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) Alzheimers Research UK, ARUK-PG2013-2, Research Associate 2 years.</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lambert</surname><given-names initials="C">Christian</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>Oxford Handbook of Neurology - 2nd Edition, Oxford University Press, 2014</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benjamin</surname><given-names initials="P">Philip</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brookes</surname><given-names initials="RL">Rebecca L.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>British Heart Foundation Project Grant (Ref CRM:0006031).</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mackinnon</surname><given-names initials="AD">Andrew D.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morris</surname><given-names initials="RG">Robin G.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>Cortex Associate Editor</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>P1Vital consultant</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barrick</surname><given-names initials="TR">Thomas R.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><contrib contrib-type="author"><name name-style="western"><surname>Markus</surname><given-names initials="HS">Hugh S.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p>
<list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Editorial Boards:</title><list-item><p>Section editor International Journal of stroke Editorial board Clin Neurology and Neurosurgery and BMC Medicine Associate Editor Frontiers in Neurology</p></list-item></list>
</p><p>
<list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Publishing Royalties:</title><list-item><p>Stroke Medicine OUP. 2016</p></list-item></list>
</p><p>
<list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Consultancies:</title><list-item><p>Astra Zeneca &gt;$1000</p></list-item></list>
</p><p>
<list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Other activities:</title><list-item><p>Reimbursement from Astra Zeneca for teaching session to employees</p></list-item></list>
</p><p>
<list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>MRC experimental medicine grant 2016-20 NIHR Senior Investigator and NIHR HTA Grant</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Stroke Association, EU, Wellcome Trust, The British Heart Foundation, Alzheimer Research UK for peer reviewed research grants</p></list-item></list>
</p><p>
<list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list>
</p><p>
<list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list>
</p></author-comment></contrib><aff>From the Neuroscience Research Centre (E.A.Z., C.L., P.B., T.R.B.), Cardiovascular and Cell Sciences Research Institute, St George's University of London; Stroke Research Group (A.J.L., R.L.B., H.S.M.), Clinical Neurosciences, University of Cambridge; Atkinson Morley Regional Neuroscience Centre (A.D.M.), St George's NHS Healthcare Trust; and Department of Psychology (R.G.M.), King's College Institute of Psychiatry, Psychology, and Neuroscience, London, UK.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Zeestraten: <email>p1207006@sgul.ac.uk</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004594" ext-link-type="uri">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing charge was funded by Wellcome Trust.</p></fn></author-notes><pub-date pub-type="ppub"><day>31</day><month>10</month><year>2017</year></pub-date><volume>89</volume><issue>18</issue><issue-id pub-id-type="pmc-issue-id">300781</issue-id><fpage>1869</fpage><lpage>1876</lpage><history><date date-type="received"><day>29</day><month>9</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2017</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>10</month><year>2017</year></date></event><event event-type="pmc-live"><date><day>03</day><month>11</month><year>2017</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-18 00:25:14.500"><day>18</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="NEUROLOGY2016772202.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="pdf" xlink:href="NEUROLOGY2016772202.pdf"/><abstract><sec><title>Objective:</title><p>To determine whether MRI markers, including diffusion tensor imaging (DTI), can predict cognitive decline and dementia in patients with cerebral small vessel disease (SVD).</p></sec><sec><title>Methods:</title><p>In the prospective St George's Cognition and Neuroimaging in Stroke study, multimodal MRI was performed annually for 3 years and cognitive assessments annually for 5 years in a cohort of 99 patients with SVD, defined as symptomatic lacunar stroke and confluent white matter hyperintensities (WMH). Progression to dementia was determined in all patients. Progression of WMH, brain volume, lacunes, cerebral microbleeds, and a DTI measure (the normalized peak height of the mean diffusivity histogram distribution) as a marker of white matter microstructural damage were determined.</p></sec><sec><title>Results:</title><p>Over 5 years of follow-up, 18 patients (18.2%) progressed to dementia. A significant change in all MRI markers, representing deterioration, was observed. The presence of new lacunes, and rate of increase in white matter microstructural damage on DTI, correlated with both decline in executive function and global functioning. Growth of WMH and deterioration of white matter microstructure on DTI predicted progression to dementia. A model including change in MRI variables together with their baseline values correctly classified progression to dementia with a C statistic of 0.85.</p></sec><sec><title>Conclusions:</title><p>This longitudinal prospective study provides evidence that change in MRI measures including DTI, over time durations during which cognitive change is not detectable, predicts cognitive decline and progression to dementia. It supports the use of MRI measures, including DTI, as useful surrogate biomarkers to monitor disease and assess therapeutic interventions.</p></sec></abstract><funding-group><award-group><funding-source>Wellcome Trust grant</funding-source><award-id>081589</award-id></award-group><award-group><funding-source>National Institute of Health Research</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>special-property</meta-name><meta-value>podcast</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Cerebral small vessel disease (SVD) is the major pathology underlying vascular dementia and an important cause of age-related cognitive decline.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> While many elderly patients develop radiologic signs of SVD,<sup><xref rid="R2" ref-type="bibr">2</xref></sup> only a minority progress to dementia. Better methods are required to identify the subgroup who rapidly decline.</p><p>Using rate of cognitive decline as a predictive tool in SVD has been shown to be limited<sup><xref rid="R3" ref-type="bibr">3</xref></sup> due to the slow rate of decline<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and insensitivity of cognitive tests to change. Research has therefore focused on using MRI features of SVD, such as lacunes, white matter hyperintensities (WMH), and brain atrophy,<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> as surrogate markers.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Diffusion tensor imaging (DTI) is of particular interest; it is highly sensitive to white matter (WM) microstructural damage in SVD and demonstrates widespread abnormalities in the apparently normal-appearing WM (NAWM).<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p>Cross-sectional studies have shown that both lacunes and diffuse WM damage detected on DTI are associated with cognitive impairment.<sup><xref rid="R9" ref-type="bibr">9</xref><xref rid="R10" ref-type="bibr">–</xref><xref rid="R12" ref-type="bibr">12</xref></sup> It has been hypothesized that both result in white matter track disruption, and disconnection of distributed networks underlying executive function (EF) and processing speed (PS), the 2 domains most affected in SVD.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> However, almost all previous data are cross-sectional and therefore give information only on association, not prediction. The longitudinal St George's Cognition and Neuroimaging in Stroke (SCANS) study was established to determine whether change in multimodal MRI, including DTI, predicts cognitive decline and dementia in SVD.</p><sec sec-type="methods" id="s1"><title>METHODS</title><sec id="s1-1"><title>Patients.</title><p>Details of the SCANS study have been published previously.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> In brief, patients presenting with symptomatic SVD, defined as a clinical lacunar stroke syndrome<sup><xref rid="R15" ref-type="bibr">15</xref></sup> with MRI evidence of an anatomically corresponding lacunar infarct, and with confluent regions of WMH graded ≥2 on the modified Fazekas scale,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> were enrolled from 3 stroke services covering a geographically contiguous region in South London. Patients underwent MRI annually for 3 years and cognitive testing annually for 5 years. At each visit, repeat recordings of cardiovascular risk factors and blood pressure were performed. Data on progression to dementia were collected during follow-up and from hospital and family doctor records.</p><sec id="s1-1-1"><title>Standard protocol approvals, registrations, and patient consents.</title><p>The study was approved by the Wandsworth (London) research ethics committee and all patients provided written informed consent. The study is registered with the UK Clinical Research Network (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://public.ukcrn.org.uk/" ext-link-type="uri">public.ukcrn.org.uk/</ext-link>; study ID 4577).</p></sec><sec id="s1-1-2"><title>Available data.</title><p>A total of 121 patients were recruited. Of these, 103 attended more than one cognitive assessment. Eighteen patients only attended one assessment due to death (n = 7), study withdrawal (n = 6), house move (n = 1), lost to follow-up (n = 2), or withdrawal from full neuropsychological testing (n = 2). Of the 103 who attended cognitive assessments more than once, MRI data at multiple time points were available for 99; 4 withdrew from imaging but remained in the study for neuropsychological testing. In this analysis, we describe the relationship between change of MRI measures and both cognitive change and progression to dementia in all 99 who had at least one follow-up MRI. The number of complete MRI and cognitive assessments at each time point are shown in table e-1 at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004594" ext-link-type="uri">Neurology.org</ext-link>.</p><p>Demographic characteristics of the 99 patients (<xref rid="T1" ref-type="table">table 1</xref>) who attended one or more follow-up MRI and cognitive sessions compared to the 22 who did not have been described previously.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> There were no significant differences in any imaging measures between the groups, but patients who remained in the study were younger and had higher baseline Mini-Mental State Examination (MMSE) scores. At study entry, no patients had had intracerebral hemorrhage, had superficial siderosis, or met the modified Boston criteria for definite, probable, or possible cerebral amyloid angiopathy.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Baseline and change characteristics of the analyzed cohort</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="NEUROLOGY2016772202TT1.jpg"/></table-wrap></sec></sec><sec id="s1-2"><title>MRI acquisition.</title><p>MRI at baseline and each follow-up visit were acquired using the same 1.5T GE Signa HDxt system (General Electric, Milwaukee, WI) using identical image acquisition protocols as previously published<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and described in appendix e-1.</p></sec><sec id="s1-3"><title>MRI analysis.</title><sec id="s1-3-1"><title>Structural preprocessing.</title><p>A longitudinal tissue segmentation pipeline optimized to our SVD cohort, described in detail in a previous publication,<sup><xref rid="R18" ref-type="bibr">18</xref></sup> was performed to obtain segmentations for gray matter, NAWM, WMH, and CSF based on coregistered fluid-attenuated inversion recovery and T1-weighted images.</p></sec><sec id="s1-3-2"><title>Conventional MRI markers of SVD.</title><p>The tissue segmentation maps were used to calculate total cerebral volume and WMH lesion load (log-transformed to adjust for its skewed distribution). Lacunes and cerebral microbleeds (CMB) were identified by a trained independent rater according to agreed neuroimaging standards.<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Detailed calculations and descriptions for these MRI markers are shown in appendix e-2.</p></sec><sec id="s1-3-3"><title>Diffusion preprocessing.</title><p>Detailed preprocessing steps of diffusion-weighted images have been described elsewhere<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and in appendix e-3. Preprocessing was applied to evaluate the normalized mean diffusivity (MD) histogram distributions of all WM tissue (i.e., NAWM plus WMH) (range 0–0.004 mm<sup>2</sup>/s, bin width 0.000004 mm<sup>2</sup>/s). The normalized frequency of voxels with the histogram peak value in all WM tissue, the MD normalized peak height (MD-NPH) (figure e-1), was used as a measure of tissue microstructure over time as we have previously shown it is the most stable and sensitive DTI measure of change.<sup><xref rid="R20" ref-type="bibr">20</xref></sup></p></sec></sec><sec id="s1-4"><title>Cognitive assessment.</title><sec id="s1-4-1"><title>Cognitive index scores.</title><p>A battery of well-established, standardized tasks sensitive to the cognitive impairments seen in SVD was carried out annually. Full details have been published previously.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> In brief, cognitive tasks (table e-2) were age-scaled using published normative data, converted to <italic toggle="yes">z</italic> scores, and grouped into broad cognitive domains. Averaging across component scores within each cognitive domain created cognitive index scores for EF, PS, working memory, and long-term memory. An overall global functioning score based on all administered tests was produced. In addition, premorbid intelligence was assessed.</p></sec><sec id="s1-4-2"><title>Dementia.</title><p>Information on conversion to dementia was available for all 99 patients. Dementia was diagnosed using the DSM-5<sup><xref rid="R21" ref-type="bibr">21</xref></sup> definition of major neurocognitive disorder, and was present if individuals met one of the following criteria:<list list-type="order"><list-item><p>A diagnosis of dementia made in a memory clinic or equivalent clinical service</p></list-item><list-item><p>After review of medical records and cognitive assessments by a neurologist and clinical neuropsychologist, both blinded to MRI and risk factor information, who agreed that the clinical picture met DSM-5 criteria</p></list-item><list-item><p>An MMSE score consistently &lt;24, indicative of cognitive impairment,<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and reduced capabilities in daily living as measured by a score ≤7 on the Instrumental Activities of Daily Living (IADL)<sup><xref rid="R23" ref-type="bibr">23</xref></sup></p></list-item></list></p><p>The presence of dementia was determined before comparison of cognitive and MRI data. Date of dementia onset was defined as the date of diagnosis. If no exact date was known and dementia conversion was based on review of patient data or cognitive performance, the midpoint date between the visit at which the diagnosis was established and the previous visit was used.</p></sec></sec><sec id="s1-5"><title>Statistical analyses.</title><p>We employed linear mixed effect (LME) models to estimate annualized change rates in MRI and cognitive markers based on all available time points. MRI and cognitive indices data were modeled separately in MLwiN 2.1 (Centre for Multilevel Modelling, University of Bristol).<sup><xref rid="R24" ref-type="bibr">24</xref></sup> Intercepts and linear trajectories (i.e., annual change rate) across the follow-up period as a function of time were allowed to vary with fixed and random effects. The presence of detectable change was assessed on the basis of significance of the average fixed effect slope of time evaluated using a Wald test. Slopes for each patient as estimated by the LME models were extracted and used for further analyses.</p><p>First, univariate linear regression analyses were performed between annualized cognitive change rates and MRI markers using SPSS 22.0 (IBM Corp., Armonk, NY). Lacunes and CMB were treated as binary variables (i.e., no change or any new lesions), due to the low frequency of new lesions. Multivariate stepwise linear regression analysis was used to investigate the relationship between annualized change rates of different MRI markers with cognitive decline. Baseline age, premorbid IQ, and sex were added as covariates.</p><p>Predictive abilities of MRI change rates and vascular risk factors for dementia conversion were assessed by univariate Cox regression. LME estimates of change in MRI variables for these dementia models were recalculated to exclude MRI data acquired after conversion to dementia (n = 3 participants, n = 3 observations). This ensured that only imaging data prior to diagnosis were used to predict dementia conversion. Continuous risk factors, such as blood pressure, were averaged over all time points. Smoking status was defined as smoking during the majority of follow-up, and diabetes as presence at any point during follow-up. A stepwise multivariate Cox regression model including all annualized MRI change rates and risk factors, plus baseline age, premorbid IQ, and sex, was applied to identify independent predictors of dementia.</p><p>To assess classification performance of the regression model, we performed discriminant function analyses. First we identified the discriminant value of a conventional risk factor model including age, sex, premorbid IQ, and cardiovascular risk factors. Subsequently we compared significance, sensitivity and specificity, area under the receiver operating characteristic curve (AUC; equivalent to a C statistic),<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and model stability (i.e., through leave-one-out cross-validation) of that model to that of a model that included the significant variables from the multivariate Cox regression and their baseline values (the relationship between baseline MRI measures and cognition is not investigated in this article, but has been previously published for the 121 patients recruited<sup><xref rid="R10" ref-type="bibr">10</xref></sup>).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Conversion to dementia.</title><p>A total of 18 (18.2%) of 99 patients converted to dementia during the 5-year follow-up. Dementia diagnosis was based on clinical diagnosis (n = 8), review of medical records (n = 3), and meeting dementia thresholds for MMSE and IADL scores (n = 7). Mean (SD) time to dementia conversion was 3.31 ± 1.40 years. Deaths and other endpoints during follow-up are shown in appendix e-4.</p></sec><sec id="s2-2"><title>Change in MRI and cognitive measures.</title><p>Over the 3-year imaging period, there was an increase in WMH lesion load, worsening of WM tissue microstructure (decreased MD-NPH), and decreased brain volume (<xref rid="T1" ref-type="table">table 1</xref>). Seventy-four new lacunes were observed in 27 patients. Nineteen developed 1–2 lacunes, and 8 ≥3 (maximum 9). A total of 173 new CMB occurred in 35 individuals; 10 developed a single CMB, 14 developed 2–5 CMB, and 11 developed ≥6 CMB.</p><p>During 5-year cognitive follow-up, there was a statistically significant decline in EF, PS, and global functioning (<xref rid="T1" ref-type="table">table 1</xref>). No change in working and long-term memory was observed. We therefore limited further analyses to EF, PS, and global functioning. Cognitive change varied markedly between individual patients, with some showing marked decline and others no decline. Estimated annualized progression rates are shown in <xref rid="F1" ref-type="fig">figure 1</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><title>Estimated annual change rates for cognitive indices</title><p>The dot lines show all estimated individual annual progression rates of executive function, processing speed, and global functioning, as modeled using linear mixed effect models over all available time points.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="NEUROLOGY2016772202FF1.jpg"/></fig></sec><sec id="s2-3"><title>Relationship between imaging change and cognition change.</title><p>Univariate models showed decline in EF was associated with lower baseline premorbid IQ (β = 0.219, <italic toggle="yes">p</italic> = 0.026), greater change of MD-NPH (β = 0.275, <italic toggle="yes">p</italic> = 0.007), and new lacunes (β = −0.269, <italic toggle="yes">p</italic> = 0.003) but not brain volume (β = −0.030, <italic toggle="yes">p</italic> = 0.773) or CMB (β = −0.190, <italic toggle="yes">p</italic> = 0.061) or WMH (β = 0.077, <italic toggle="yes">p</italic> = 0.449). In contrast, no neuroimaging marker, age, IQ, or sex correlated with decline in PS. Decline in global functioning was associated with lower premorbid IQ (β = 0.307, <italic toggle="yes">p</italic> = 0.002), greater change in MD-NPH (β = 0.262, <italic toggle="yes">p</italic> = 0.011), new lacunes (β = −0.265, <italic toggle="yes">p</italic> = 0.004), and new CMB (β = −0.218, <italic toggle="yes">p</italic> = 0.035) but not WMH (β = 0.677, <italic toggle="yes">p</italic> = 0.500) or brain volume (β = −0.113, <italic toggle="yes">p</italic> = 0.277).</p><p><xref rid="T2" ref-type="table">Table 2</xref> shows standardized regression coefficients from multivariate models investigating which MRI markers correlated with cognitive decline. New lacunes, decline in MD-NPH, and premorbid IQ were independently associated with decline in EF. The model explained 17.9% of variance in EF change (<italic toggle="yes">F</italic><sub>3,91</sub> = 6.63, <italic toggle="yes">p</italic> &lt; 0.001). Age, premorbid IQ, change in MD-NPH, and new lacunes were all independent correlates of decline in global functioning, with the model explaining 26.6% of variance (<italic toggle="yes">F</italic><sub>4,88</sub> = 7.98, <italic toggle="yes">p</italic> &lt; 0.001).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Independent predictors of change in cognitive indices</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="NEUROLOGY2016772202TT2.jpg"/></table-wrap></sec><sec id="s2-4"><title>Imaging predictors of conversion to dementia.</title><p>Univariate Cox regression analyses revealed only greater MD-NPH change (hazard ratio 0.004; <italic toggle="yes">p</italic> = 0.034) was indicative of conversion to dementia (<xref rid="T3" ref-type="table">table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Predictors of conversion to dementia in cerebral small vessel disease</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="NEUROLOGY2016772202TT3.jpg"/></table-wrap><p>On multivariate Cox regression including all MRI measures, as well as age, sex, IQ, and vascular risk factors, only higher premorbid IQ, greater increase in WMH, and greater decrease in MD-NPH independently predicted conversion to dementia (<xref rid="T3" ref-type="table">table 3</xref>).</p></sec><sec id="s2-5"><title>Dementia prediction accuracy.</title><p>Discriminant analysis in which age, sex, and premorbid IQ and vascular risk factors were entered did not discriminate between dementia converters and nonconverters (Wilks lambda [<italic toggle="yes">df</italic> 9] = 0.865, χ<sup>2</sup> = 13.43, <italic toggle="yes">p</italic> = 0.144). In contrast, discriminant analysis including the MRI variables found to be associated with progression to dementia in the previous multivariate Cox regression (i.e., change in MD-NPH, WMH, and premorbid IQ) and their MRI baseline values was significant (Wilks lambda [<italic toggle="yes">df</italic> 5] = 0.759, χ<sup>2</sup> = 24.64; <italic toggle="yes">p</italic> &lt; 0.001). It correctly classified 80.9% of patients with 80.0% sensitivity and 81.0% specificity and achieved an AUC of 0.849, corresponding to a C statistic of 0.849. After leave-one-out cross-validation, this model remained stable, with a sensitivity of 73.3% and specificity of 78.5%.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>In this longitudinal prospective study in symptomatic SVD, change in multimodal MRI measures over a 3-year period, during which little change in cognition was detectable, predicted long-term cognitive decline and dementia. In particular, diffuse WM damage on DTI predicted decline in EF and progression to dementia. It was striking that while some patients had marked cognitive decline, others did not decline. This emphasizes the need for predictive tools to identify those who are likely to develop dementia both for individual risk prediction and to identify who may benefit from specific treatments. Our results suggest that MRI may be useful in risk prediction.</p><p>Previous cross-sectional studies using DTI have demonstrated abnormalities not only within WMH,<sup><xref rid="R26" ref-type="bibr">26</xref></sup> but also in NAWM,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> and have shown these DTI measures correlate with cognition more strongly than WMH volume.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> This finding, indicating that diffuse WM damage is associated with cognitive decline, has led to the hypothesis that disruption of WM tracks and secondary disconnection of complex cortical–subcortical networks causes cognitive impairment. However, cross-sectional studies demonstrate association, but cannot prove causality. Longitudinal studies provide stronger evidence that associations are causal. This study provides some of the first evidence that change in DTI measures correlates with subsequent cognitive decline in SVD, and therefore provides support for the hypothesis that diffuse WM damage on DTI causes cognitive impairment.</p><p>Using discriminant analysis, we showed that WM microstructure in addition to WMH lesion load and premorbid IQ had significant power to discriminate dementia converters from nonconverters with a C statistic of 0.849. This is a level of prediction that would be clinically useful and is, for example, higher than the 0.81 previously reported for an all-dementia model, which included MRI variables in addition to demographic, vascular risk factor, and cognitive variables.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Replication in further independent SVD test populations is needed.</p><p>Our results provide further support for the validity of MRI measures as surrogate markers in clinical trials evaluating new treatments for SVD. Currently there are few effective treatments for patients with SVD-related cognitive decline. A major obstacle to assessing new treatments is the lack of detectable longitudinal change in cognition over short time periods.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> This has led to the suggestion that MRI measures may be useful to assess new therapies.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R30" ref-type="bibr">30</xref></sup> Using MRI markers could markedly reduce sample sizes required to detect treatment effects.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> However, before such a surrogate marker is adopted clinically, it is essential to show that change in the marker correlates with change in clinical endpoints. Our study provides some of the first data that this is indeed the case with change in MD-NPH, the DTI measure most sensitive to change,<sup><xref rid="R20" ref-type="bibr">20</xref></sup> correlating with eventual cognitive decline and progression to dementia.</p><p>Previous cross-sectional studies in SVD have shown that, in addition to WM damage imaged on DTI, lacunar infarcts<sup><xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref></sup> and brain volume<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> are also associated with cognitive impairment, while inconsistent associations have been shown for CMB.<sup><xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> In this study, new lacunar infarcts were associated with decline in EF. Although 74 new lacunar infarcts were detected over 3 years of imaging follow-up, only 3 patients had symptomatic lacunar strokes in this period. Therefore, although the vast majority of new lacunar infarcts are apparently asymptomatic, they are associated with cognitive decline. It has been hypothesized that lacunar infarcts do so by causing previously mentioned disconnection.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Support for this has been provided by cross-sectional data showing that network efficiency mediates the association of lacunar infarcts on cognitive impairment.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> In contrast to previous cross-sectional data, we did not find any association between brain volume and cognitive decline or dementia despite a detectable decline in volume over time.</p><p>Previous studies have shown little or no cognitive change over shorter time periods in this patient group.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> An analysis of cognition at 3 years in the same SCANS study showed minimal detectable change,<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and in the large SPS3 trial in MRI-confirmed lacunar stroke no change was detected over a 2-year period either.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The current study shows that with longer follow-up, change is detectable. The lack of cognitive change over shorter periods of time is likely to be a reflection of testing methodology (i.e., variability in test results and learning effects), as well as the slow rate of cognitive decline in some individuals.</p><p>In contrast to associations we found between DTI measures and EF, we found no association with decline in PS. This is perhaps surprising in light of the association between PS and MRI measures in previous cross-sectional studies.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> This may reflect the relatively large motor performance component in our PS measure leading to reduced specificity. Alternatively, the mechanisms underlying PS impairment in SVD might differ from those causing EF impairment. PS impairment has been shown to associate with global efficiency derived from DTI tractography networks,<sup><xref rid="R14" ref-type="bibr">14</xref></sup> and may be a consequence of more diffuse network disruption. Decline in PS may thus be better described by alternative analysis methods such as network analysis.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p><p>The present study had a number of limitations. First, it suffered from moderate data loss during follow-up, although the dropout rate is comparable to longitudinal aging studies.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> As reported previously, patients without complete follow-up tended to be older and more disabled,<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> which may have led to an underestimation of MRI and cognitive progression rates. Second, all MRI data were acquired on a 1.5T scanner. Although the same scanner was used, which was not upgraded during the duration of the study, image data quality could be improved by higher field strengths and spatial resolution with isotropic voxel dimensions.<sup><xref rid="R39" ref-type="bibr">39</xref></sup> SVD represents a spectrum of disease from asymptomatic WMH in community populations through to patients with multiple lacunes and extensive WMH who present with vascular dementia.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> This study investigated a population with moderate to severe symptomatic SVD who have a higher risk of progressing to dementia. In this specific patient group, we showed that a significant proportion progresses to dementia over 5 years. Our results now require replication in patients with less severe SVD, such as in community studies, in which WM DTI measures have been shown to correlate with cognition cross-sectionally.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R40" ref-type="bibr">40</xref></sup></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data" position="float" orientation="portrait"><caption><title>Data Supplement</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="text" mime-subtype="html" xlink:href="supp_89_18_1869__index.html" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_WNL.0000000000004594_Figure_e-1.pdf" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Appendix_e-1.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Appendix_e-2.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Appendix_e-3.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Appendix_e-4.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_e-References.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Table_e-1.docx" position="float" orientation="portrait"/><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_WNL.0000000000004594_Table_e-2.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors thank Dr. Lalit Kalra and Dr. Tony Rudd for help with recruitment.</p></ack><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004594" ext-link-type="uri">Neurology.org</ext-link></p></fn></fn-group><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">Concept and design of study: E.A.Z., R.L.B., R.G.M., T.R.B., H.S.M. Data acquisition and analysis: E.A.Z., A.J.L., C.L., P.B., A.D.M. Manuscript preparation: E.A.Z., A.J.L., C.L., P.B., R.L.B., R.G.M., T.R.B., H.S.M.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">Supported by Wellcome Trust grant (081589). Recruitment was supported by the English National Institute of Health Research (NIHR) Clinical Stroke Research Network. The Article Processing Charge was funded by the Wellcome Trust.</p></sec><sec sec-type="coi-statement"><title>DISCLOSURE</title><p>E. Zeestraten reports no disclosures relevant to the manuscript. A. Lawrence is supported by a project grant from Alzheimer's Research UK (ARUK-EXT2015B-1). C. Lambert and P. Benjamin report no disclosures relevant to the manuscript. R. Brookes is supported by a British Heart Foundation Project Grant (PG/13/30/30005). A. Mackinnon, R. Morris, and T. Barrick report no disclosures relevant to the manuscript. H. Markus is supported by an NIHR Senior Investigator award and his work is supported by the Cambridge University Hospital Comprehensive NIHR Biomedical Research Unit. Go to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://neurology.org/lookup/doi/10.1212/WNL.0000000000004594" ext-link-type="uri">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">AUC</term><def><p>area under the receiver operating characteristic curve</p></def></def-item><def-item><term id="G2">CMB</term><def><p>cerebral microbleeds</p></def></def-item><def-item><term id="G3">DSM-5</term><def><p>
<italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders, 5th edition</italic>
</p></def></def-item><def-item><term id="G4">DTI</term><def><p>diffusion tensor imaging</p></def></def-item><def-item><term id="G5">EF</term><def><p>executive function</p></def></def-item><def-item><term id="G6">IADL</term><def><p>Instrumental Activities of Daily Living</p></def></def-item><def-item><term id="G7">LME</term><def><p>linear mixed effect</p></def></def-item><def-item><term id="G8">MD</term><def><p>mean diffusivity</p></def></def-item><def-item><term id="G9">MMSE</term><def><p>Mini-Mental State Examination</p></def></def-item><def-item><term id="G10">NAWM</term><def><p>normal-appearing white matter</p></def></def-item><def-item><term id="G11">NPH</term><def><p>normalized peak height</p></def></def-item><def-item><term id="G12">PS</term><def><p>processing speed</p></def></def-item><def-item><term id="G13">SCANS</term><def><p>St George's Cognition and Neuroimaging in Stroke</p></def></def-item><def-item><term id="G14">SVD</term><def><p>small vessel disease</p></def></def-item><def-item><term id="G15">WM</term><def><p>white matter</p></def></def-item><def-item><term id="G16">WMH</term><def><p>white matter hyperintensities</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pantoni</surname><given-names>L</given-names></string-name></person-group>. <article-title>Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges</article-title>. <source>Lancet Neurol</source><year>2010</year>;<volume>9</volume>:<fpage>689</fpage>–<lpage>701</lpage>.<pub-id pub-id-type="pmid">20610345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(10)70104-6</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Debette</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis</article-title>. <source>BMJ</source><year>2010</year>;<volume>341</volume>:<fpage>c3666</fpage>.<pub-id pub-id-type="pmid">20660506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.c3666</pub-id><pub-id pub-id-type="pmcid">PMC2910261</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pearce</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>McClure</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>DC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial</article-title>. <source>Lancet Neurol</source><year>2014</year>;<volume>13</volume>:<fpage>1177</fpage>–<lpage>1185</lpage>.<pub-id pub-id-type="pmid">25453457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70224-8</pub-id><pub-id pub-id-type="pmcid">PMC4284947</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Brookes</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Zeestraten</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Pattern and rate of cognitive decline in cerebral small vessel disease: a prospective study</article-title>. <source>PLoS One</source><year>2015</year>;<volume>10</volume>:<fpage>e0135523</fpage>.<pub-id pub-id-type="pmid">26273828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0135523</pub-id><pub-id pub-id-type="pmcid">PMC4537104</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker</article-title>. <source>Int J Stroke</source><year>2011</year>;<volume>6</volume>:<fpage>47</fpage>–<lpage>59</lpage>.<pub-id pub-id-type="pmid">21205241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1747-4949.2010.00552.x</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wardlaw</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>EE</given-names></string-name>, <string-name name-style="western"><surname>Biessels</surname><given-names>GJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration</article-title>. <source>Lancet Neurol</source><year>2013</year>;<volume>12</volume>:<fpage>822</fpage>–<lpage>838</lpage>.<pub-id pub-id-type="pmid">23867200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(13)70124-8</pub-id><pub-id pub-id-type="pmcid">PMC3714437</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benjamin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zeestraten</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Progression of MRI markers in cerebral small vessel disease: sample size considerations for clinical trials</article-title>. <source>J Cereb Blood Flow Metab</source><year>2016</year>;<volume>36</volume>:<fpage>228</fpage>–<lpage>240</lpage>.<pub-id pub-id-type="pmid">26036939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2015.113</pub-id><pub-id pub-id-type="pmcid">PMC4758545</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O'Sullivan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Summers</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Jarosz</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>SCR</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study</article-title>. <source>Neurology</source><year>2001</year>;<volume>57</volume>:<fpage>2301</fpage>–<lpage>2310</lpage>.<pub-id pub-id-type="pmid">11756617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.57.12.2307</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nitkunan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lanfranconi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Charlton</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Brain atrophy and cerebral small vessel disease: a prospective follow-up study</article-title>. <source>Stroke</source><year>2011</year>;<volume>42</volume>:<fpage>133</fpage>–<lpage>138</lpage>.<pub-id pub-id-type="pmid">21148440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.110.594267</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Mechanisms of cognitive impairment in cerebral small vessel disease: multimodal MRI results from the St George's Cognition and Neuroimaging in Stroke (SCANS) study</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>:<fpage>e61014</fpage>.<pub-id pub-id-type="pmid">23613774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0061014</pub-id><pub-id pub-id-type="pmcid">PMC3632543</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Josephson</surname><given-names>SA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Subcortical lacunes are associated with executive dysfunction in cognitively normal elderly</article-title>. <source>Stroke</source><year>2008</year>;<volume>39</volume>:<fpage>397</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">18096844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.491795</pub-id><pub-id pub-id-type="pmcid">PMC2443738</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jokinen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Lipsanen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study</article-title>. <source>Neurology</source><year>2012</year>;<volume>78</volume>:<fpage>1785</fpage>–<lpage>1792</lpage>.<pub-id pub-id-type="pmid">22592361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182583070</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>O'Sullivan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Summers</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>SCR</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Evidence for cortical “disconnection” as a mechanism of age-related cognitive decline</article-title>. <source>Neurology</source><year>2001</year>;<volume>57</volume>:<fpage>632</fpage>–<lpage>638</lpage>.<pub-id pub-id-type="pmid">11524471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.57.4.632</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Morris</surname><given-names>RG</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name></person-group>. <article-title>Structural network efficiency is associated with cognitive impairment in small vessel disease</article-title>. <source>Neurology</source><year>2014</year>;<volume>44</volume>:<fpage>1</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000612</pub-id><pub-id pub-id-type="pmcid">PMC4115608</pub-id><pub-id pub-id-type="pmid">24951477</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bamford</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sandercock</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Warlow</surname><given-names>C</given-names></string-name></person-group>. <article-title>The natural history of lacunar infarction: the Oxfordshire Community Stroke Project</article-title>. <source>Stroke</source><year>1987</year>;<volume>18</volume>:<fpage>545</fpage>–<lpage>551</lpage>.<pub-id pub-id-type="pmid">3590244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.str.18.3.545</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fazekas</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Chawluk</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Alavi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hurtig</surname><given-names>HI</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>RA</given-names></string-name></person-group>. <article-title>MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging</article-title>. <source>Am J Roentgenol</source><year>1987</year>;<volume>149</volume>:<fpage>351</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">3496763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/ajr.149.2.351</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Linn</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Halpin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Demaerel</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy</article-title>. <source>Neurology</source><year>2010</year>;<volume>74</volume>:<fpage>1346</fpage>–<lpage>1350</lpage>.<pub-id pub-id-type="pmid">20421578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181dad605</pub-id><pub-id pub-id-type="pmcid">PMC2875936</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lambert</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Benjamin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Zeestraten</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Longitudinal patterns of leukoaraiosis and brain atrophy in symptomatic small vessel disease</article-title>. <source>Brain</source><year>2016</year>;<volume>139</volume>:<fpage>1136</fpage>–<lpage>1151</lpage>.<pub-id pub-id-type="pmid">26936939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/aww009</pub-id><pub-id pub-id-type="pmcid">PMC4806220</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cordonnier</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Potter</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>CA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Improving interrater agreement about brain microbleeds: development of the brain observer microbleed scale (BOMBS)</article-title>. <source>Stroke</source><year>2009</year>;<volume>40</volume>:<fpage>94</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">19008468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.108.526996</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zeestraten</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Benjamin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Application of diffusion tensor imaging parameters to detect change in longitudinal studies in cerebral small vessel disease</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<fpage>e0147836</fpage>.<pub-id pub-id-type="pmid">26808982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0147836</pub-id><pub-id pub-id-type="pmcid">PMC4726604</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="book"><collab>American Psychiatric Association</collab>. <source>Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5)</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tombaugh</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>McIntyre</surname><given-names>NJ</given-names></string-name></person-group>. <article-title>The Mini-Mental State Examination: a comprehensive review</article-title>. <source>J Am Geriatr Soc</source><year>1992</year>;<volume>40</volume>:<fpage>922</fpage>–<lpage>935</lpage>.<pub-id pub-id-type="pmid">1512391</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1992.tb01992.x</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barberger-Gateau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Commenger</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gagnon</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Letenneur</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sauvel</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dartigues</surname><given-names>J-F</given-names></string-name></person-group>. <article-title>Instrumental Activities of Daily Living as a screening tool for cognitive impairment and dementia in elderly community dwellers</article-title>. <source>J Am Geriatr Soc</source><year>1992</year>;<volume>40</volume>:<fpage>1129</fpage>–<lpage>1134</lpage>.<pub-id pub-id-type="pmid">1401698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1532-5415.1992.tb01802.x</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Rasbash</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Charlton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Browne</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Healy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cameron</surname><given-names>B</given-names></string-name></person-group>. <source>MLwiN Version 2.1. Centre for Multilevel Modelling</source>. <publisher-loc>Bristol</publisher-loc>: <publisher-name>University of Bristol</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hanley</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>McNeil</surname><given-names>BJ</given-names></string-name></person-group>. <article-title>The meaning and use of the area under a receiver operating characteristic (ROC) curve</article-title>. <source>Radiology</source><year>1982</year>;<volume>143</volume>:<fpage>29</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">7063747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1148/radiology.143.1.7063747</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Lythgoe</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Horsfield</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>SCR</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Characterization of white matter damage in ischemic leukoaraiosis with diffusion tensor MRI</article-title>. <source>Stroke</source><year>1999</year>;<volume>30</volume>:<fpage>393</fpage>–<lpage>397</lpage>.<pub-id pub-id-type="pmid">9933277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.str.30.2.393</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>della Nave</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Foresti</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pratesi</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Whole-brain histogram and voxel-based analyses of diffusion tensor imaging in patients with leukoaraiosis: correlation with motor and cognitive impairment</article-title>. <source>AJNR Am J Neuroradiol</source><year>2007</year>;<volume>28</volume>:<fpage>1313</fpage>–<lpage>1319</lpage>.<pub-id pub-id-type="pmid">17698534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3174/ajnr.A0555</pub-id><pub-id pub-id-type="pmcid">PMC7977673</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nitkunan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Charlton</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time</article-title>. <source>Stroke</source><year>2008</year>;<volume>39</volume>:<fpage>1999</fpage>–<lpage>2005</lpage>.<pub-id pub-id-type="pmid">18436880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.107.507475</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Barnes</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Covinsky</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Whitmer</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Kuller</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>OL</given-names></string-name>, <string-name name-style="western"><surname>Yaffe</surname><given-names>K</given-names></string-name></person-group>. <article-title>Predicting risk of dementia in older adults: the late-life dementia risk index</article-title>. <source>Neurology</source><year>2009</year>;<volume>73</volume>:<fpage>173</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">19439724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3181a81636</pub-id><pub-id pub-id-type="pmcid">PMC2715571</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmidt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Seiler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Loitfelder</surname><given-names>M</given-names></string-name></person-group>. <article-title>Longitudinal change of small-vessel disease-related brain abnormalities</article-title>. <source>J Cereb Blood Flow Metab</source><year>2016</year>;<volume>36</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jcbfm.2015.72</pub-id><pub-id pub-id-type="pmcid">PMC4758559</pub-id><pub-id pub-id-type="pmid">25899293</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Viswanathan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gschwendtner</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Guichard</surname><given-names>J-P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Lacunar lesions are independently associated with disability and cognitive impairment in CADASIL</article-title>. <source>Neurology</source><year>2007</year>;<volume>69</volume>:<fpage>172</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">17620550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000265221.05610.70</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benjamin</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lambert</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Strategic lacunes and their relationship to cognitive impairment in cerebral small vessel disease</article-title>. <source>Neuroimage Clin</source><year>2014</year>;<volume>4</volume>:<fpage>828</fpage>–<lpage>837</lpage>.<pub-id pub-id-type="pmid">24936433</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nicl.2014.05.009</pub-id><pub-id pub-id-type="pmcid">PMC4055894</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Viswanathan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Godin</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Jouvent</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of MRI markers in subcortical vascular dementia: a multi-modal analysis in CADASIL</article-title>. <source>Neurobiol Aging</source><year>2010</year>;<volume>31</volume>:<fpage>1629</fpage>–<lpage>1636</lpage>.<pub-id pub-id-type="pmid">18926602</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurobiolaging.2008.09.001</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Patel</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>AW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cerebral microbleeds and cognition in patients with symptomatic small vessel disease</article-title>. <source>Stroke</source><year>2013</year>;<volume>44</volume>:<fpage>356</fpage>–<lpage>361</lpage>.<pub-id pub-id-type="pmid">23321452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.112.670216</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Werring</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Frazer</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Coward</surname><given-names>LJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRI</article-title>. <source>Brain</source><year>2004</year>;<volume>127</volume>:<fpage>2265</fpage>–<lpage>2275</lpage>.<pub-id pub-id-type="pmid">15282216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awh253</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tuladhar</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>van Dijk</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zwiers</surname><given-names>MP</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Structural network connectivity and cognition in cerebral small vessel disease</article-title>. <source>Hum Brain Mapp</source><year>2016</year>;<volume>37</volume>:<fpage>300</fpage>–<lpage>310</lpage>.<pub-id pub-id-type="pmid">26466741</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hbm.23032</pub-id><pub-id pub-id-type="pmcid">PMC6867512</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schmidt</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ropele</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferro</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study</article-title>. <source>Stroke</source><year>2010</year>;<volume>41</volume>:<fpage>402</fpage>–<lpage>408</lpage>.<pub-id pub-id-type="pmid">20203319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.109.576629</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Glymour</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Chěne</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Tzourio</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Dufouil</surname><given-names>C</given-names></string-name></person-group>. <article-title>Brain MRI markers and dropout in a longitudinal study of cognitive aging: the Three-City Dijon Study</article-title>. <source>Neurology</source><year>2012</year>;<volume>79</volume>:<fpage>1340</fpage>–<lpage>1348</lpage>.<pub-id pub-id-type="pmid">22972647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e31826cd62a</pub-id><pub-id pub-id-type="pmcid">PMC3448743</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vrenken</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jenkinson</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Horsfield</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis</article-title>. <source>J Neurol</source><year>2013</year>;<volume>260</volume>:<fpage>2458</fpage>–<lpage>2471</lpage>.<pub-id pub-id-type="pmid">23263472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-012-6762-5</pub-id><pub-id pub-id-type="pmcid">PMC3824277</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hannesdottir</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nitkunan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Charlton</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Barrick</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>MacGregor</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Markus</surname><given-names>HS</given-names></string-name></person-group>. <article-title>Cognitive impairment and white matter damage in hypertension: a pilot study</article-title>. <source>Acta Neurol Scand</source><year>2009</year>;<volume>119</volume>:<fpage>261</fpage>–<lpage>268</lpage>.<pub-id pub-id-type="pmid">18798828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0404.2008.01098.x</pub-id></mixed-citation></ref></ref-list></back></article>